Pachymic acid alleviates hepatic lipid accumulation and oxidative stress in MASLD via regulation of the Keap1–Nrf2–HO-1 signaling axis
Frontiers in Nutrition · 18.08.2026 · 13
DOI: 10.3389/fnut.2026.1887176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 18.08.2026. Verfasst von Maoru Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Key Laboratory of Chinese Medicine Processing, College of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rapidly growing metabolic disorder with no FDA-approved treatment. Pachymic acid (PA; synonym: 3-O-acetyltumulosic acid), a lanostane-type triterpenoid, shows potential for treating MASLD. However, its mechanisms remain underexplored.
Objective
This work evaluated the therapeutic efficacy and mechanisms of PA in treating MASLD.
Methods
The high-cholesterol diet (HCD)-induced zebrafish model, high-fat diet induced C57BL/6 mice model and free fatty acid (FFA)-treated BRL-3A cells was used to assess PA’s anti- MASLD effects in vivo and in vitro .
Results
PA improved lipid metabolism disrupted by HCD, reduced hepatic oxidative stress, as indicated by decreased MDA levels and increased SOD activity, and lowered inflammatory markers, including TNF- α , IL-6, and IL-1β. PA also enhanced antioxidant activity by regulating the Keap1-Nrf2-HO-1 pathway. PA decreased Keap1 mRNA expression induced by reactive oxygen species (ROS), upregulated Nrf2 and HO-1 expression, and promoted Nrf2 nuclear translocation. These effects suggest that PA inhibits ROS production by activating the Keap1-Nrf2-HO-1 pathway and possibly by inhibiting Nrf2 degradation.
Conclusion
PA improves MASLD through lipid metabolism regulation and antioxidant effects, primarily by activating the Keap1-Nrf2-HO-1 pathway. These findings highlight PA’s potential as a therapeutic agent for MASLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yunnan Key Laboratory of Chinese Medicine Processing, College of Chinese Materia Medica, Yunnan University of Chinese Medicine, Kunming, China.
- School of Life Science and Technology, Kunming University of Science and Technology, Kunming, China.
Zitieren
APA
Li, M., Wang, Z., Zhai, H., Li, J., Ma, J., & Qiu, B. (2026). Pachymic acid alleviates hepatic lipid accumulation and oxidative stress in MASLD via regulation of the Keap1–Nrf2–HO-1 signaling axis. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1887176
Vancouver
Li M, Wang Z, Zhai H, Li J, Ma J, Qiu B. Pachymic acid alleviates hepatic lipid accumulation and oxidative stress in MASLD via regulation of the Keap1–Nrf2–HO-1 signaling axis. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1887176
BibTeX
@article{Li2026,
author = {Li, Maoru and Wang, Zefeng and Zhai, Huan and Li, Jiajiao and Ma, Ji and Qiu, Bin},
title = {Pachymic acid alleviates hepatic lipid accumulation and oxidative stress in MASLD via regulation of the Keap1–Nrf2–HO-1 signaling axis},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1887176}
}
EUVIMED